

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

CHANGE OF PROPOSED APPOINTMENT OF DIRECTOR OF THE FIFTH SESSION OF THE BOARD

Reference is made to the announcement of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”) dated March 28, 2023 in relation to, among other things, the proposed appointments of the fifth session of the Board (the “**Announcement**”). Unless otherwise indicated, capitalized terms used in this announcement shall have the same meaning as those defined in the Announcement.

Mr. Zhang Wensheng has withdrawn from the election as a candidate for independent non-executive Directors of the fifth session of the Board due to personal reasons. In accordance with relevant provisions of the Company Law and the Articles of Association, at the 33rd meeting of the fourth session of the Board convened on April 25, 2023, the resolution on the proposed appointment of Mr. Yuan Huagang as an independent non-executive Director of the fifth session of the Board was considered and approved.

Biography details of Mr. Yuan Huagang, a candidate for independent non-executive Directors of the fifth session of the Board are set out as follows:

Mr. Yuan Huagang (袁華剛), aged 49, is well versed in the relevant laws, regulations and rules of the capital market in China, and has long been engaged in M&A and restructuring and various innovative businesses and has engaged in and led many investment and investment banking projects with impact.

Mr. Yuan served in various positions at Guotai Junan Securities Co., Ltd. (a company listed on the Stock Exchange, stock code: 2611) from July 2000 to 2015, including executive director of investment banking department, managing director, deputy general manager and sponsor representative. He served as a director of EVE Energy Co., Ltd. (惠州億緯鋰能股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 300014) from October 2016 to October 2022. He has served as the managing partner and a member of the Investment Decision-making Committee of Zhejiang United Investment Group* (浙江民營企業聯合投資股份有限公司) since June 2015.

Mr. Yuan has been an independent director of Shanghai Xinhua Media Co., Ltd. (上海新華傳媒股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 600825) since October 2020. Mr. Yuan has been a director and the general manager of Pacific Shuanglin Bio-pharmacy Co., Ltd. (派斯雙林生物製藥股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 000403) since March 2022.

Mr. Yuan obtained the PRC lawyer qualification (non-practising) certificate in August 1998, and obtained the qualification for sponsor representative of the Securities Association of China (中國證券業協會) in May 2009.

Mr. Yuan obtained his bachelor's degree in economics from Zhejiang University in July 1997 and a master's degree in business administration in banking and finance from University of Macau in December 1999.

Mr. Yuan Huagang has confirmed that, save as disclosed above: (i) he does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (ii) he has no relationship with any other Directors, Supervisors, senior management, substantial or controlling shareholders of the Company; and (iii) as at the date of this announcement, he does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO.

Mr. Yuan Huagang has also confirmed that there is no other information in relation to his appointment that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his appointment that needs to be brought to the attention of the Shareholders.

The term of office of the fifth session of the Board shall be three years, commencing from the date when the relevant resolutions are approved at the general meeting. If appointed, Mr. Yuan Huagang, a proposed independent non-executive Director of the fifth session of the Board, is entitled to RMB200,000 (tax inclusive) per annum, which is determined in accordance with the Company's remuneration policy and with reference to the level of remuneration paid by comparable companies, the time commitment of the Director, duties and responsibilities in the Group, his qualification and experience. He is entitled to travel expenses to attend relevant meetings and events of the Company and expenses incurred in the exercise of his duties in accordance with the Articles of Association. The Company will also disclose the total remuneration received by the Director in the annual report accordingly. After the appointment of Mr. Yuan Huagang comes into effect, the Company will enter into a service contract with him.

In accordance with the requirements of relevant laws, regulations and the Articles of Association, the above-mentioned proposed appointment of the Director of the fifth session of the Board is subject to the approval by the Shareholders at the general meeting.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, April 25, 2023

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive Directors are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.